Please assess the completion status of the following clinical trial:

Trial Title: Subcutaneous Immunotherapy With Dermatophagoides Pteronyssinus in Local Allergic Rhinitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Prior to study specific examinations the patient has to give his/her written informed consent.~* Local allergic rhinitis induced by Dermatophagoides pteronyssinus (DP).~* Age: 18-55.~* Negative skin prick-test to DP~* Positive nasal allergen provocation test to DP (NAPT-DP) and/or nasal specific IgE (sIgE) to DP\>0.35 kU/L~* If applicable negative urine pregnancy test and willingness to use effective form of contraception for the duration of involvement in the study.~Exclusion Criteria:~* Severe immunopathological or immunodeficiencies diseases.~* Treatment with beta-blockers, even when administered topically~* Severe psychological disorders~* Severe Atopic Dermatitis~* FEV1 \<70% predicted after appropriate pharmacological treatment~* History of hypersensitivity or intolerance to excipients and / or trial medication or other medication to be used for protocol~* Inability to adequately perform diagnostic tests or treatment~* Awareness of other inhaled allergens (perennial or seasonal) clinically relevant to the subject and that may interfere with the response evaluation~* Treatment with immunotherapy in the 5 years prior to his inclusion in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Pangramin Plus D. pteronyssinus (Type: ACTIVE_COMPARATOR): Pangramin Plus D. pteronyssinus 100% for subcutaneous injection
- Placebo (Type: PLACEBO_COMPARATOR): Placebo for subcutaneous injection

Based on this trial design, predict the completion outcome and termination type (if applicable).